In this study, we mainly performed 16S sequencing on fecal samples of NSCLC patients who received anti‐PD‐1 therapy combined with chemotherapy to explore whether there were significant changes in the intestinal flora of NSCLC patients after the combination therapy. Here, PDCD1 is linked to non-small cell lung carcinoma.